Cargando…
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection
The novel coronavirus, SARS-CoV-2 that causes COVID-19 has resulted in the death of nearly 4 million people within the last 18 months. While preventive vaccination, and monoclonal antibody therapies have been rapidly developed and deployed, early in the pandemic the use of COVID-19 convalescent plas...
Autores principales: | Clark, Natasha M., Janaka, Sanath Kumar, Hartman, William, Stramer, Susan, Goodhue, Erin, Weiss, John, Evans, David T., Connor, Joseph P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903276/ https://www.ncbi.nlm.nih.gov/pubmed/35259162 http://dx.doi.org/10.1371/journal.pone.0257930 |
Ejemplares similares
-
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.
por: Clark, Natasha M, et al.
Publicado: (2021) -
Transient IgA, steady IgG?
por: Berthold, Dorothée L., et al.
Publicado: (2020) -
IgG deposition in IgA nephropathy patients
por: Nasri, Hamid
Publicado: (2013) -
Linear IgA and IgG bullous dermatosis
por: Fernandes, Karina de Almeida Pinto, et al.
Publicado: (2016) -
Lower Levels of ABO Anti-A and Anti-B of IgM, IgG and IgA Isotypes in the Serum but Not the Saliva of COVID-19 Convalescents
por: Matzhold, Eva M., et al.
Publicado: (2022)